Skip to main content

Table 1 Patient characteristics and preoperative data

From: Palliative bypass surgery for patients with advanced pancreatic adenocarcinoma: experience from a tertiary center

 n = 42
Gender, m/f (ratio)23/19 (1.21)
Age (average ± SD)70.5 ± 11.44
BMI (average ± SD)23.97 ± 5.23
Metastatic disease, n (%)21 (50)
 Intra-abdominal metastasis14 (33.3)
 Liver metastasis10 (23.8)
 Extra-abdominal metastasis2 (4.7)
Locally advanced disease only, n (%)21 (50)
Comorbidities, n (%)
 HTN24 (57.14)
 DM17 (40.4)
 HPL17 (40.4)
 IHD9 (21.4)
 CHF2 (4.7)
 CKD3 (7.14)
 CVA4 (9.4)
 BPH3 (7.14)
 COPD1 (2.35)
 Smoking10 (23.8)
 Obesity3 (7.14)
Past abdominal surgery, n (%)10 (23.8)
Preop chemotherapy, n (%)13 (30.9)
Preop PTD, n (%)4 (9.4)
Preop ERCP, n (%)11 (26.2)
Preop surgical exploration, n (%)5 (11.9)
Preop albumin (mean ± SD)34.6 ± 4.94
Preop albumin< 30, n (%)6 (14.28)
Preop bilirubin> 1, n (%)14 (33.3)
  1. BMI body mass index, HTN hypertension, DM diabetes mellitus, IHD ischemic heart disease, CHF congestive heart failure, CKD chronic kidney disease, HPL hyperlipidemia, BPH benign prostate hypertrophy, CVA cerebrovascular accident, COPD chronic obstructive pulmonary disease, PTD percutaneous transhepatic drainage, ERCP endoscopic retrograde cholangiopancreatography